Possible Association of ABCB1:c.3435T>C Polymorphism with High-density-lipoprotein-cholesterol Response to Statin Treatment--a Pilot Study

Overview

Journal Bosn J Basic Med Sci

Specialty General Medicine

Date 2014 Aug 31

PMID 25172973

Citations 8

Authors

Anna Salacka

Agnieszka Binczak-Kuleta

Mariusz Kaczmarczyk

Iwona Hornowska

Krzysztof Safranow

Jeremy S C Clark

Affiliations

Soon will be listed here.

Abstract

The gene product ABCB1 (formerly MDR1 or P-glycoprotein) is hypothesized to be involved in cholesterol cellular trafficking, redistribution and intestinal re-absorption. Carriers of the ABCB1:3435T allele have previously been associated with decreases in ABCB1 mRNA and protein concentrations and have been correlated with changes in serum lipid concentrations. The aim of this study was to investigate possible association between the ABCB1:3435T>C polymorphism and changes in lipids in patients following statin treatment. Outpatients (n=130) were examined: 43 men (33%), 87 women (67%): treated with atorvastatin or simvastatin (all patients with equivalent dose of 20 or 40 mg/d simvastatin). Blood was taken for ABCB1:3435T>C genotyping, and before and after statin treatment for lipid concentration determination (total cholesterol, high-density-lipoprotein-cholesterol (HDL-C), triglycerides). Change (Δ) in lipid parameters, calculated as differences between measurements before and after treatment, were analyzed with multiple regression adjustments: gender, diabetes, age, body mass index, equivalent statin dose, length of treatment. Univariate and multivariate analyses showed significant differences in ΔHDL-C (univariate p=0.029; multivariate p=0.036) and %ΔHDL-C (univariate p=0.021; multivariate p=0.023) between patients with TT (-0.05 ± 0.13 g/l; -6.8% ± 20%; respectively) and CC+CT genotypes (0.004 ± 0.15 g/l; 4.1 ± 26%; respectively). Reduction of HDL-C in homozygous ABCB1:3435TT patients suggests this genotype could be associated with a reduction in the benefits of statin treatment.

Citing Articles

Insights into the genetic architecture of haematological traits from deep phenotyping and whole-genome sequencing for two Mediterranean isolated populations.

Kuchenbaecker K, Gilly A, Suveges D, Southam L, Giannakopoulou O, Kilian B Sci Rep. 2022; 12(1):1131.

PMID: 35064169 PMC: 8782863. DOI: 10.1038/s41598-021-04436-9.

An association of ABCG8: rs11887534 polymorphism and HDL-cholesterol response to statin treatment in the Polish population.

Salacka A, Boron A, Goracy I, Hornowska I, Safranow K, Ciechanowicz A Pharmacol Rep. 2021; 73(6):1781-1786.

PMID: 34173968 PMC: 8599229. DOI: 10.1007/s43440-021-00302-7.

The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.

Leon-Cachon R, Bamford A, Meester I, Barrera-Saldana H, Gomez-Silva M, Garcia Bustos M Sci Rep. 2020; 10(1):8900.

PMID: 32483134 PMC: 7264171. DOI: 10.1038/s41598-020-65843-y.

Interactions Between Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.

Tryggvadottir H, Huzell L, Gustbee E, Simonsson M, Markkula A, Jirstrom K Front Oncol. 2018; 8:428.

PMID: 30370250 PMC: 6194198. DOI: 10.3389/fonc.2018.00428.

Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins.

Danielak D, Karazniewicz-Lada M, Glowka F Drugs. 2018; 78(11):1105-1112.

PMID: 30003466 PMC: 6061431. DOI: 10.1007/s40265-018-0947-x.

References

Hoffmeyer S, Burk O, von Richter O, Arnold H, Brockmoller J, Johne A . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97(7):3473-8. PMC: 16264. DOI: 10.1073/pnas.97.7.3473. View

Barter P, OBrien R . Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis. 2000; 149(1):199-205. DOI: 10.1016/s0021-9150(99)00402-5. View

Jones P, Kafonek S, Laurora I, Hunninghake D . Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81(5):582-7. DOI: 10.1016/s0002-9149(97)00965-x. View

Hung C, Tai J, Lin C, Lee M, Liou H . Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005; 6(4):411-7. DOI: 10.1517/14622416.6.4.411. View

Garrigues A, Escargueil A, Orlowski S . The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A. 2002; 99(16):10347-52. PMC: 124917. DOI: 10.1073/pnas.162366399. View

Willey V, Reinhold J, Willey K, Kelly B, Cziraky M . Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice. Int J Clin Pract. 2010; 64(9):1235-8. DOI: 10.1111/j.1742-1241.2010.02423.x. View

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y . Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008; 9(2):167-74. DOI: 10.2174/138920008783571756. View

Keskitalo J, Kurkinen K, Neuvoneni P, Niemi M . ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2009; 84(4):457-61. DOI: 10.1038/clpt.2008.25. View

10.

Kajinami K, Brousseau M, Ordovas J, Schaefer E . Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol. 2004; 93(8):1046-50. DOI: 10.1016/j.amjcard.2004.01.014. View

11.

Tanigawara Y . Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000; 22(1):137-40. DOI: 10.1097/00007691-200002000-00029. View

12.

Gotto Jr A . Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol. 2005; 96(5A):34F-38F. DOI: 10.1016/j.amjcard.2005.06.010. View

13.

Fung K, Gottesman M . A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009; 1794(5):860-71. PMC: 2810319. DOI: 10.1016/j.bbapap.2009.02.014. View

14.

Sever P, Poulter N, Dahlof B, Wedel H, Collins R, Beevers G . Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005; 28(5):1151-7. DOI: 10.2337/diacare.28.5.1151. View

15.

Ni L, Li J, Miao K, Qiao C, Zhang S, Qiu H . Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2010; 28(1):265-9. DOI: 10.1007/s12032-010-9456-9. View

16.

Shou W, Wang D, Zhang K, Wang B, Wang Z, Shi J . Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese population. PLoS One. 2012; 7(9):e46295. PMC: 3458811. DOI: 10.1371/journal.pone.0046295. View

17.

Markova S, Nakamura T, Sakaeda T, Makimoto H, Uchiyama H, Okamura N . Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metab Pharmacokinet. 2006; 21(3):194-200. DOI: 10.2133/dmpk.21.194. View

18.

Rodrigues A, Rebecchi I, Bertolami M, Faludi A, Hirata M, Hirata R . High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res. 2005; 38(9):1389-97. DOI: 10.1590/s0100-879x2005000900014. View

19.

Ballantyne C, Blazing M, Hunninghake D, Davidson M, Yuan Z, Delucca P . Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003; 146(5):862-9. DOI: 10.1016/S0002-8703(03)00440-X. View

20.

Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A . Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002; 72(2):209-19. DOI: 10.1067/mcp.2002.126177. View